Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

Immunocore Holdings PLC Sponsored ADR (IMCR) reported $97.96 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 29.9%. EPS of -$0.20 for the same period compares to -$0.23 a year ago.The reported revenue represents a surprise of +5.74% over the Zacks Consensus Estimate of $92.64 million. With the consensus EPS estimate being -$0.21, the EPS surprise was +4.76%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Immunocore performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic Revenue- United States: $64.09 million versus $59.44 million estimated by two analysts on average.Geographic Revenue- International: $0.84 million versus the two-analyst average estimate of $4.92 million.Geographic Revenue- Europe: $33.04 million versus $28.27 million estimated by two analysts on average.View all Key Company Metrics for Immunocore here>>>Shares of Immunocore have returned -7.2% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks